Advertisement







Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2009; 53:184-192, doi:10.1016/j.jacc.2008.09.031
© 2009 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Online Appendix
Right arrow View Related Cardiosource Journal Scan
Right arrow View Talk Back
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (5)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hernandez, A. F.
Right arrow Articles by Fonarow, G. C.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Hernandez, A. F.
Right arrow Articles by Fonarow, G. C.
Related Collections
Right arrowRelated Articles

CLINICAL RESEARCH: HEART FAILURE

Clinical Effectiveness of Beta-Blockers in Heart Failure

Findings From the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure) Registry

Adrian F. Hernandez, MD, MHS*,{dagger},*, Bradley G. Hammill, MS*, Christopher M. O'Connor, MD, FACC*,{dagger}, Kevin A. Schulman, MD*,{dagger}, Lesley H. Curtis, PhD*,{dagger} and Gregg C. Fonarow, MD, FACC{ddagger}

* Duke Clinical Research Institute, Durham, North Carolina
{dagger} Department of Medicine, Duke University School of Medicine, Durham, North Carolina
{ddagger} Ahmanson-UCLA Cardiomyopathy Center, Department of Medicine, UCLA Medical Center, Los Angeles, California

Manuscript received April 25, 2008; revised manuscript received August 25, 2008, accepted September 22, 2008.

* Reprint requests and correspondence: Dr. Adrian F. Hernandez, Duke Clinical Research Institute, P.O. Box 17969, Durham, North Carolina 27715 (Email: adrian.hernandez{at}duke.edu).

Objectives: We sought to examine associations between initiation of beta-blocker therapy and outcomes among elderly patients hospitalized for heart failure.

Background: Beta-blockers are guideline-recommended therapy for heart failure, but their clinical effectiveness is not well understood, especially in elderly patients.

Methods: We merged Medicare claims data with OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure) records to examine long-term outcomes of eligible patients newly initiated on beta-blocker therapy. We used inverse probability–weighted Cox proportional hazards models to determine the relationships among treatment and mortality, rehospitalization, and a combined mortality–rehospitalization end point.

Results: Observed 1-year mortality was 33%, and all-cause rehospitalization was 64%. Among 7,154 patients hospitalized with heart failure and eligible for beta-blockers, 3,421 (49%) were newly initiated on beta-blocker therapy. Among patients with left ventricular systolic dysfunction (LVSD) (n = 3,001), beta-blockers were associated with adjusted hazard ratios of 0.77 (95% confidence interval [CI]: 0.68 to 0.87) for mortality, 0.89 (95% CI: 0.80 to 0.99) for rehospitalization, and 0.87 (95% CI: 0.79 to 0.96) for mortality–rehospitalization. Among patients with preserved systolic function (n = 4,153), beta-blockers were associated with adjusted hazard ratios of 0.94 (95% CI: 0.84 to 1.07) for mortality, 0.98 (95% CI: 0.90 to 1.06) for rehospitalization, and 0.98 (95% CI: 0.91 to 1.06) for mortality–rehospitalization.

Conclusions: In elderly patients hospitalized with heart failure and LVSD, incident beta-blocker use was clinically effective and independently associated with lower risks of death and rehospitalization. Patients with preserved systolic function had poor outcomes, and beta-blockers did not significantly influence the mortality and rehospitalization risks for these patients.

Key Words: adrenergic beta-antagonists • heart failure • mortality patient readmission

Abbreviations and Acronyms
  ACE = angiotensin-converting enzyme
  ARB = angiotensin receptor blocker
  CI = confidence interval
  LVEF = left ventricular ejection fraction
  LVSD = left ventricular systolic dysfunction


Related Articles

Beta-Blockers in Elderly Patients With Heart Failure: Ready for Prime Time?
Mitja Lainscak, Hans-Dirk Duengen, and Stefan D. Anker
J. Am. Coll. Cardiol. 2009 54: 2202. [Full Text] [PDF]

Stainless Steel Stents and Magnetic Resonance Imaging: Looking Into a Black Hole
Damien Kenny, Mark C.K. Hamilton, and Robin P. Martin
J. Am. Coll. Cardiol. 2009 54: 2202-2203. [Full Text] [PDF]

Inside This Issue of JACC
J. Am. Coll. Cardiol. 2009 53: A24. [Full Text] [PDF]



This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
W. J. Paulus and J. J.M. van Ballegoij
Treatment of Heart Failure With Normal Ejection Fraction: An Inconvenient Truth!
J. Am. Coll. Cardiol., February 9, 2010; 55(6): 526 - 537.
[Abstract] [Full Text] [PDF]


Home page
Mayo Clin Proc.Home page
G. V. Ramani, P. A. Uber, and M. R. Mehra
Chronic Heart Failure: Contemporary Diagnosis and Management
Mayo Clin. Proc., February 1, 2010; 85(2): 180 - 195.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
M. Lainscak, H.-D. Duengen, and S. D. Anker
Beta-Blockers in Elderly Patients With Heart Failure Ready for Prime Time?
J. Am. Coll. Cardiol., December 1, 2009; 54(23): 2202 - 2202.
[Full Text] [PDF]


Home page
CirculationHome page
C. Tschope and W. J. Paulus
Doppler Echocardiography Yields Dubious Estimates of Left Ventricular Diastolic Pressures
Circulation, September 1, 2009; 120(9): 810 - 820.
[Full Text] [PDF]


Home page
Eur J Heart FailHome page
J. G.F. Cleland, A. P. Coletta, A. Torabi, and A. L. Clark
Clinical trials update from the European Society of Cardiology heart failure meeting 2009: CHANCE, B-Convinced, CHAT, CIBIS-ELD, and Signal-HF
Eur J Heart Fail, August 1, 2009; 11(8): 802 - 805.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
J. M. Kramer, L. H. Curtis, C. S. Dupree, A. F. Hernandez, M. Massing, and K. J. Anstrom
Eligibility Criteria for {beta}-Blockade Might Have to Be Taken Into Account--Reply
Arch Intern Med, June 8, 2009; 169(11): 1078 - 1078.
[Full Text] [PDF]


Home page
Arch Intern MedHome page
O. M. P. Jolobe
Eligibility Criteria for {beta}-Blockade Might Have to Be Taken Into Account
Arch Intern Med, June 8, 2009; 169(11): 1077 - 1078.
[Full Text] [PDF]


Home page
Br Med BullHome page
J.-C. Tardif
Heart rate as a treatable cardiovascular risk factor
Br. Med. Bull., June 1, 2009; 90(1): 71 - 84.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
A. F. Hernandez and G. C. Fonarow
BNP-Guided Heart Failure Therapy in Older Patients
JAMA, May 27, 2009; 301(20): 2091 - 2092.
[Full Text] [PDF]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement